started · updated
WHO issues new guidelines for GLP-1 obesity treatments
The World Health Organization (WHO) has issued new guidelines regarding the use of GLP-1 medications and bariatric surgery for obesity. The organization explicitly prohibits these treatments for children aged zero to nine. However, it states that severely overweight adolescents aged ten to 19 may safely use weight-reduction medications under specific, strictly defined conditions when conservative treatments have failed.
The rise in GLP-1 usage is driving significant shifts in consumer behavior and industry strategies. In the United States, adult usage rose to 11% in 2026 from 3% in 2024, with households using these drugs spending 4% less on groceries. Retailers like The Giant Company are introducing nutritional guidance services to assist users, while food manufacturers like Kraft Heinz are reformulating products with higher protein and fiber.
In Brazil, GLP-1 use surged by 244% in the first half of 2026 compared to the previous year. This trend has impacted the beauty sector, with a 29.4% increase in medicated shampoo sales. Data also indicates that the informal market accounts for approximately 53.8% of GLP-1 doses consumed in Brazil. Meanwhile, in Germany, demand for the new Wegovy semaglutide tablets has remained low following their release.
Entities
Eli Lilly · European Academy of Dermatology and Venereology · FDA · GLP-1 receptor agonists · Kraft Heinz · Novo Nordisk · Scanntech · The GIANT Company · University of Edinburgh · World Health Organization · Zocdoc
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] The GLP-1 market is projected to reach $185.3 billion by 2033. www.fool.com
- [○ 1 SOURCE] Patients booking an initial GLP-1 consultation are 21% more likely to book additional medical care over the following 12 months. abc17news.com
- [○ 1 SOURCE] An international survey found 39% of GLP-1 users reported nail detachment compared to 9% of nonusers. www.medicaldaily.com
- [○ 1 SOURCE] Measured risk factors explain no more than half of the reduction in serious cardiovascular events seen with semaglutide. www.thepharmacist.co.uk
- [○ 1 SOURCE] Current GLP-1 medications can achieve body weight reductions of 10% to 15%, comparable to bariatric surgery. www.pharmexec.com
- [● 3 SOURCES] The percentage of US adults using GLP-1 medications rose to 11% in 2026 from 3% in 2024. theshelbyreport.com · krdo.com
- [● 3 SOURCES] Demand for the new Wegovy weight loss tablets in Germany has been low since their introduction. www.leinetal24.de · www.volksfreund.de
- [● 3 SOURCES] The weekly injection version of the medication offers advantages over the daily tablet version. www.leinetal24.de · www.volksfreund.de
- [● 3 SOURCES] The Wegovy tablet containing semaglutide was released in German pharmacies on September 1, 2026. www.leinetal24.de · www.volksfreund.de
- [● 3 SOURCES] The weight loss tablet requires strict administration rules, including fasting for 8 hours before and after intake. www.leinetal24.de · www.volksfreund.de
- [● 2 SOURCES] The WHO states that severely overweight adolescents can safely be treated with weight-reduction medications under specific conditions. www.fehmarn24.de · www.kosmo.at
- [○ 1 SOURCE] The informal market accounts for approximately 53.8% of GLP-1 doses consumed in Brazil. ascoferj.com.br